Cathy Eng, MD

Articles

Dr. Eng on the Rationale for Studying the Impact of RAS Mutations in Early Onset Resectable CRC

May 21st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Dr. Eng on Surgical Considerations for RAS-Mutant CRC

May 19th 2021

Cathy Eng, MD, FACP, FASCO, discusses surgical considerations for patients with RAS-mutant colorectal cancer.

Dr. Eng on the Impact of RAS Mutations on Outcomes in Early vs Late CRC Following Liver Resection

May 17th 2021

Cathy Eng, MD, FACP, FASCO, discusses the impact of RAS mutations on outcomes in patients with early vs late colorectal cancer following liver resection.

Dr. Eng on Extended RAS Analysis Results From the EPIC Trial in mCRC

March 17th 2021

Cathy Eng, MD, FACP, FASCO, discusses results from the extended RAS analysis of the phase 3 EPIC trial in patients with metastatic colorectal cancer.

Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

March 16th 2021

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Dr. Eng on Future Research Efforts in Adjuvant CRC

December 21st 2020

Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

November 19th 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC

April 17th 2019

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Dr. Eng on the Treatment Landscape in Metastatic Colorectal Cancer

February 13th 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. Eng on Ongoing Studies for BRAF-Mutant CRC

January 3rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

November 10th 2017

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

Dr. Eng on Emerging Agents for Treatment of Anal Cancer

February 8th 2016

Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.

Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer

December 17th 2015

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.